Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 5 |
| List of Tables | 5 | 1 |
| List of Figures | 6 | 1 |
| Introduction | 7 | 1 |
| Global Markets Direct Report Coverage | 7 | 1 |
| Degenerative Disc Disease Overview | 8 | 1 |
| Therapeutics Development | 9 | 2 |
| Pipeline Products for Degenerative Disc Disease Overview | 9 | 1 |
| Pipeline Products for Degenerative Disc Disease Comparative Analysis | 10 | 1 |
| Degenerative Disc Disease Therapeutics under Development by Companies | 11 | 1 |
| Degenerative Disc Disease Therapeutics under Investigation by Universities/Institutes | 12 | 1 |
| Degenerative Disc Disease Pipeline Products Glance | 13 | 4 |
| Late Stage Products | 13 | 1 |
| Clinical Stage Products | 14 | 1 |
| Early Stage Products | 15 | 1 |
| Unknown Stage Products | 16 | 1 |
| Degenerative Disc Disease Products under Development by Companies | 17 | 1 |
| Degenerative Disc Disease Products under Investigation by Universities/Institutes | 18 | 1 |
| Degenerative Disc Disease Companies Involved in Therapeutics Development | 19 | 10 |
| AnGes MG, Inc. | 19 | 1 |
| Asterias Biotherapeutics, Inc. | 20 | 1 |
| Biogenomics Limited | 21 | 1 |
| Biopharm GmbH | 22 | 1 |
| BioRestorative Therapies, Inc. | 23 | 1 |
| Bone Therapeutics SA | 24 | 1 |
| DiscGenics, Inc. | 25 | 1 |
| ISTO Technologies, Inc. | 26 | 1 |
| TissueGene, Inc. | 27 | 1 |
| Yuhan Corporation | 28 | 1 |
| Degenerative Disc Disease Therapeutics Assessment | 29 | 9 |
| Assessment by Monotherapy Products | 29 | 1 |
| Assessment by Target | 30 | 2 |
| Assessment by Mechanism of Action | 32 | 2 |
| Assessment by Route of Administration | 34 | 2 |
| Assessment by Molecule Type | 36 | 2 |
| Drug Profiles | 38 | 21 |
| ALLOB Drug Profile | 38 | 3 |
| AMG-0101 Drug Profile | 41 | 2 |
| AMG-0103 Drug Profile | 43 | 1 |
| BRTX-100 Drug Profile | 44 | 2 |
| CHND-1 Drug Profile | 46 | 1 |
| dibotermin alfa Drug Profile | 47 | 1 |
| NuQu Drug Profile | 48 | 1 |
| Peptides to Antagonize IL-1 Receptor for Dermatology, Musculoskeletal and CNS Disorders Drug Profile | 49 | 1 |
| Poly N-Acetyl Glucosamine Hydrogel Drug Profile | 50 | 1 |
| Recombinant Protein for Bone Fracture, Degenerative Disc Disease, Erectile Dysfunction and Parkinson's Disease Drug Profile | 51 | 2 |
| Small Molecules for Degenerative Disc Disease Drug Profile | 53 | 1 |
| Stem Cell Therapy for Degenerative Disc Disease Drug Profile | 54 | 1 |
| TG-D Drug Profile | 55 | 1 |
| X-0002 Drug Profile | 56 | 2 |
| YH-14618 Drug Profile | 58 | 1 |
| Degenerative Disc Disease Dormant Projects | 59 | 1 |
| Degenerative Disc Disease Product Development Milestones | 60 | 5 |
| Featured News &Press Releases | 60 | 1 |
| May 03, 2016: Bone Therapeutics completes recruitment of its ALLOB Phase IIA spinal fusion study | 60 | 1 |
| Feb 24, 2016: Bone Therapeutics Presents ALLOB Pre-Clinical and Early Clinical Efficacy Data in Spinal Fusion at the Clinical Applications of Stem Cells Conference | 60 | 1 |
| Feb 17, 2016: Bone Therapeutics treats 12 patients without safety concerns in ALLOB Phase IIA spinal fusion trial | 61 | 1 |
| Feb 09, 2016: BioRestorative Therapies Names Lead Cell-Based Lumbar Disc Therapeutic Product | 61 | 1 |
| Jan 12, 2015: BioRestorative Therapies Reports Successful Meeting with FDA | 62 | 1 |
| Nov 24, 2014: BioRestorative Therapies Schedules Pre-IND Meeting With FDA | 62 | 1 |
| Oct 09, 2014: BioRestorative Therapies Engages Access BIO to Support Advancement of brtxDISC Program into Clinical Studies | 63 | 1 |
| Sep 15, 2014: Bone Therapeutics receives clearance for ALLOB phase II trial in spine fusion | 63 | 2 |
| Appendix | 65 | 2 |
| Methodology | 65 | 1 |
| Coverage | 65 | 1 |
| Secondary Research | 65 | 1 |
| Primary Research | 65 | 1 |
| Expert Panel Validation | 65 | 1 |
| Contact Us | 65 | 1 |
| Disclaimer | 66 | 1 |